EXPE enters the final stretch of Q3 with bears winning the near-term argument — the stock has dropped 13% in a month to $280.70, and options traders are the most defensively positioned they have been all year.
The clearest signal is in the options market. Put demand has pushed the put/call ratio to 1.38, roughly 1.5 standard deviations above its 20-day average of 1.29 and within a whisker of its 52-week high of 1.39. That is not a panic reading, but it marks a sustained and systematic drift toward downside protection that has been building since late August, when the PCR was closer to 1.18. Options traders have been adding hedges progressively as the stock has sold off — not in a single rush of fear but as a deliberate repositioning.
Short interest tells a more measured story. Bears hold roughly 4.3% of the free float short — a level that warrants watching but is not extreme. The headline number is down sharply from late August, when it briefly touched the equivalent of around 6.3% of float, and has drifted around 5M shares for much of September. The borrow market is completely relaxed: availability is near 1,000%, meaning roughly ten shares are available for every one already borrowed, and cost to borrow is just 0.52% — about where it has been all summer. There is no squeeze pressure here, and no evidence that the short side is pressing an aggressive directional bet.
The Street is broadly constructive on a longer time horizon, but the gap between targets and the current price has narrowed uncomfortably. Most analysts revised targets sharply higher after the August earnings print — Evercore ISI moved to $430 Outperform, BTIG lifted to $400 Buy, Wedbush raised to $417 — but those calls were made when the stock was trading closer to $335. At $280.70 today, the mean target of $339 implies roughly 21% upside, which sounds generous until you note that the consensus rating is still only a Hold, with 21 Hold ratings and just one Sell. Bulls point to B2B growth momentum, improving marketing efficiency, and a strong EPS surprise track record — the company ranks in the 87th percentile on EPS surprise across the ORTEX universe. Bears counter that core B2C booking growth is a modest 7% year-on-year, US travel demand remains the dominant risk factor, and AI-enabled booking disintermediation is a slow-burn threat that is hard to price. The PE ratio has contracted by nearly 2.3 turns over the past month to 11.9x, which is either value emerging or a valuation trap depending on which camp you occupy.
The institutional register provides some ballast. BlackRock holds 8.6% of shares and added modestly through August. Barry Diller holds 4.4% and nudged his stake slightly higher as of mid-August — a founder-adjacent position that tends to act as a floor for sentiment even if it rarely drives price on its own. The WindAcre Partnership and AQR both added over 400,000 shares each in the quarter ending June, though those figures are now three months stale. On the insider side, the most recent discretionary open-market trades were sales: the CLO sold ~$336k worth on August 24, and the Chief Accounting Officer sold ~$909k worth on August 18. These were not 10b5-1 plan trades, which gives them slightly more informational weight than routine scheduled sales, though the sizes are modest relative to total compensation structures at this level.
Earnings are next on November 5. The two most recent quarterly prints produced day-one drops of 2.8% and 1.8% respectively, but both recovered to post five-day gains of 2.7% and 4.3% — a pattern where the initial reaction overshoots and the subsequent week brings buyers back in. With close peers BKNG and ABNB both down 4.1% and 3.9% on the week respectively, the weakness in EXPE is sector-wide rather than idiosyncratic, which makes the November print less about market-share dynamics and more about whether management's B2B narrative can hold up against a softening US consumer backdrop.
See the live data behind this article on ORTEX.
Open EXPE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
